Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.31 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187529 | 0.96 | MMP2 (0.33) | MMP2MMP9MMP13MTORGRM5 | |
| SCHEMBL8058980 | 0.88 | HTR2A (0.32) | PIK3R1PIK3CAHTR2A | |
| SCHEMBL973013 | 0.88 | HTR2A (0.31) | HTR2A | |
| SCHEMBL973435 | 0.88 | — | — | |
| SCHEMBL12209419 | 0.88 | — | — | |
| SCHEMBL12921205 | 0.88 | ALDH1A1 (0.30) | — | |
| SCHEMBL12921226 | 0.88 | PDE4D (0.34) | MMP2MMP9MMP13MTORSCN9A | |
| Nerandomilast SCHEMBL14734178 | 0.87 | PIK3R1 (0.34) | PIK3R1PIK3CA | |
| Nerandomilast SCHEMBL25606332 | 0.87 | PIK3R1 (0.34) | PIK3R1PIK3CA | |
| SCHEMBL8053179 | 0.87 | MTOR (0.32) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| US-11813266-B2 | Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-20230181590-A1 | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2020-02-13 | — | — | US | disclosed |
| US-20190134043-A1 | New Combination of active agents for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-05-09 | — | — | US | disclosed |
| US-20180072754-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072754-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9802954-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9802954-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20150045376-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| WO-2014124860-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20130079359-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079359-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130059866-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059866-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-07 | — | — | US | disclosed |
| WO-2013026797-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | MMP2 2398/4885MMP9 2275/4885MMP13 3449/4885 |
| US-11813266-B2 | Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | PDE3B, PDE4B, PF4 | MMP2 406/4885MMP9 208/4885MMP13 600/4885 |
| US-20180072754-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | MMP2 2398/4885MMP9 2275/4885MMP13 3449/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | MMP2 2437/4885MMP9 2008/4885MMP13 3494/4885 |
| US-20130079359-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, SQOR, TST | MMP2 2656/4885MMP9 2459/4885MMP13 3277/4885 |
| US-20190134043-A1 | New Combination of active agents for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) | PDE4B, PDE3B, PF4 | MMP2 629/4885MMP9 376/4885MMP13 924/4885 |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | PDE4B, PDE3B, PDE4A | MMP2 85/4885MMP9 281/4885MMP13 374/4885 |
| US-20230181590-A1 | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | PDE3B, PDE4B, PDE3A | MMP2 591/4885MMP9 890/4885MMP13 257/4885 |
| US-20130059866-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, SQOR, TST | MMP2 2656/4885MMP9 2459/4885MMP13 3277/4885 |
| US-20150045376-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | MMP2 2398/4885MMP9 2275/4885MMP13 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.